$NTRA

Chapman Steven Leonard sold $446K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 2,006 shares of Natera, Inc. (NTRA) at $222.25 ($0.45M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jun 6, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 6, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure may cause brief attention to insider activity, but the 10b5-1 structure generally lowers interpretive weight versus discretionary selling.

02

Market read

A planned insider sale is unlikely to be a standalone catalyst; traders may treat it as low-signal unless paired with other negative news.

03

What to watch

The article provides only one sale datapoint; without context on prior insider transactions or the size vs. total holdings, the signal may be overstated.

Relevance 7/10Novelty 6/10Timing: SEC Form 4 filed June 5 for a sale executed June 4

Background

The filing is an SEC Form 4 insider transaction by Natera’s CEO/president, executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CEO/president sold $445.8K of NTRA shares via an open-market transaction disclosed on SEC Form 4.

Expected impact

Likely limited near-term impact; any reaction should be muted unless accompanied by unusual volume or other new company news.

Evidence & confidence

Form 4 shows a small, planned sale (10b5-1) rather than an unscheduled change in insider behavior; absent other catalysts, market impact is typically modest.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with periods when insiders prefer liquidity, potentially capping upside sentiment.

Key entities

  • Natera, Inc.

    Company whose CEO/president reported an open-market sale of shares on SEC Form 4.

  • Chapman Steven Leonard

    CEO and president who sold 2,006 NTRA shares at $222.2469 on June 4, 2026.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Jim Cramer Calls Natera (NTRA) “a Promising Story”

Natera (NTRA) reported Q2 revenue of $752.8M, up 37.7% YoY, and raised its 2026 revenue forecast. Jim Cramer called it a promising precision medicine platform but advised waiting for a pullback due to valuation concerns. The company faces competition and regulatory risks, with a net loss of $67M in Q2.

$MRNAHighAI 8/10

Why Moderna's Cancer Vaccine Matters To Investors

Moderna (MRNA) and Merck (MRK) reported successful late-stage trial results for a personalized mRNA cancer vaccine targeting melanoma, reducing recurrence risk by 49%. The treatment relies on technologies from Illumina (ILMN), Danaher (DHR), and others. Moderna's stock surged 176.97% on the news, highlighting the shift toward individualized therapies in oncology.

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.